ITGAM and neoplasm: However, in both models, PLX51107 treatment significantly reduced the number of total splenocytes, the absolute number of MDSCs present in the spleen (4T1, 17.0 × 106 vs. 6.0 × 106; EMT6, 13.0 × 106 vs. 4.0 × 106; P < 0.001 for both comparisons), and the percentage of GR1+CD11b+ MDSCs within the spleen and tumor at the 15 day time point (Figure 2, A–H, and Supplemental Figure 2, E and F; P < 0.05, P < 0.01, or P < 0.001 for all comparisons).